<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603757</url>
  </required_header>
  <id_info>
    <org_study_id>Vitamin D &amp; Colorectal Cancer</org_study_id>
    <nct_id>NCT02603757</nct_id>
  </id_info>
  <brief_title>Effectiveness of High Dose Vitamin D Supplementation in Stage III Colorectal Cancer</brief_title>
  <official_title>Prospective Pilot Study to Assess the Effectiveness of Vitamin D Supplementation for Patients Requiring Chemotherapy for Stage III Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Legacy Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Legacy Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to test whether there is an association between baseline Vitamin D
      levels, Vitamin D supplementation and survival in patients with stage III colon and stage
      II/III rectal cancer receiving chemotherapy. 70 patients with colon stage III or rectal stage
      II or III cancer that require chemotherapy will be screened and 60 patients will be enrolled.
      Patients will be randomized to standard dose (2000 IU daily) or high-dose (50,000 IU weekly)
      Vitamin D supplementation for 1 year after initiation of chemotherapy. Patients' Vitamin D
      levels will be checked throughout supplementation then followed for 5 years with occasional
      Vitamin D testing and surveying in order to collect information on recurrence and survival
      outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in serum Vitamin D3 level during chemotherapy in the active supplementation group compared to the control group.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard-dose of 2,000 IU Vitamin D3, daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Higher-dose of 50,000 IU of Vitamin D3, weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  Willing to stop herbal medications as directed by physician

          -  Willing to stop current supplemental Vitamin D (Multivitamin with Vitamin D component
             is acceptable)

          -  Willing to travel to Legacy Health/OHSU facility if necessary

          -  Agree to attend study visits outside of standard of care visits, if necessary

          -  Diagnosed with stage III colon or stage II/III rectal cancer that will receive
             neoadjuvant or adjuvant chemotherapy but have not yet started

          -  Baseline serum Vitamin D level below 52 ng/ml

        Exclusion Criteria:

          -  ≤ 18 years of age

          -  Colon cancer stages I-II and IV or Rectal cancer stage I or IV

          -  Patients who do not undergo chemotherapy

          -  Patients with prior chemotherapy for this cancer

          -  No other prior malignancy except for adequately treated basal cell or squamous cell
             skin cancer, in situ cancer, or other cancer for which the patient has been
             disease-free for &gt; 3 years

          -  Unable to comply with protocol

          -  Unable to provide written informed consent

          -  Unwilling or unable to stop oral supplemental Vitamin D

          -  Patients taking high-dose Vitamin D supplementation (50,000 IU weekly) prior to
             enrollment

          -  Patients with Vitamin D levels above 52 ng/ml at baseline testing

          -  Patients with hypercalcemia and/or any condition resulting in malabsorption

          -  Investigator does not believe study participation, for any reason, is in the best
             interest of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric C Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Stubbs, BS</last_name>
    <phone>503.413.7202</phone>
    <email>jstubbs@lhs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Legacy Mount Hood Medical Center</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>503-413-8199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>503-413-8199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Legacy Meridian Park Medical Center</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>503-413-8199</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics</url>
    <description>American Cancer Society (2015). What are the key statistics about colorectal cancer?</description>
  </link>
  <link>
    <url>http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-survival-rates</url>
    <description>American Cancer Society (2015). What are the survival rates for colorectal cancer by stage?</description>
  </link>
  <reference>
    <citation>Fiscella K, Winters P, Tancredi D, Hendren S, Franks P. Racial disparity in death from colorectal cancer: does vitamin D deficiency contribute? Cancer. 2011 Mar 1;117(5):1061-9. doi: 10.1002/cncr.25647. Epub 2010 Oct 13.</citation>
    <PMID>20945439</PMID>
  </reference>
  <reference>
    <citation>Zgaga L, Theodoratou E, Farrington SM, Din FV, Ooi LY, Glodzik D, Johnston S, Tenesa A, Campbell H, Dunlop MG. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol. 2014 Aug 10;32(23):2430-9. doi: 10.1200/JCO.2013.54.5947. Epub 2014 Jul 7.</citation>
    <PMID>25002714</PMID>
  </reference>
  <reference>
    <citation>Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol. 2011 Apr 20;29(12):1599-606. doi: 10.1200/JCO.2010.31.7255. Epub 2011 Mar 21.</citation>
    <PMID>21422438</PMID>
  </reference>
  <reference>
    <citation>Brunner RL, Wactawski-Wende J, Caan BJ, Cochrane BB, Chlebowski RT, Gass ML, Jacobs ET, LaCroix AZ, Lane D, Larson J, Margolis KL, Millen AE, Sarto GE, Vitolins MZ, Wallace RB. The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr Cancer. 2011;63(6):827-41. doi: 10.1080/01635581.2011.594208. Epub 2011 Jul 20.</citation>
    <PMID>21774589</PMID>
  </reference>
  <reference>
    <citation>Fakih MG, Andrews C, McMahon J, Muindi JR. A prospective clinical trial of cholecalciferol 2000 IU/day in colorectal cancer patients: evidence of a chemotherapy-response interaction. Anticancer Res. 2012 Apr;32(4):1333-8.</citation>
    <PMID>22493367</PMID>
  </reference>
  <reference>
    <citation>Fedirko V, Bostick RM, Flanders WD, Long Q, Shaukat A, Rutherford RE, Daniel CR, Cohen V, Dash C. Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prev Res (Phila). 2009 Mar;2(3):213-23. doi: 10.1158/1940-6207.CAPR-08-0157. Epub 2009 Mar 3.</citation>
    <PMID>19258546</PMID>
  </reference>
  <reference>
    <citation>Fernandez-Garcia NI, Palmer HG, Garcia M, Gonzalez-Martin A, del Rio M, Barettino D, Volpert O, Muñoz A, Jimenez B. 1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene. 2005 Sep 29;24(43):6533-44.</citation>
    <PMID>16007183</PMID>
  </reference>
  <reference>
    <citation>Fedirko V, Bostick RM, Long Q, Flanders WD, McCullough ML, Sidelnikov E, Daniel CR, Rutherford RE, Shaukat A. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):280-91. doi: 10.1158/1055-9965.EPI-09-0448.</citation>
    <PMID>20056649</PMID>
  </reference>
  <reference>
    <citation>Bee CR, Sheerin DV, Wuest TK, Fitzpatrick DC. Serum vitamin D levels in orthopaedic trauma patients living in the northwestern United States. J Orthop Trauma. 2013 May;27(5):e103-6. doi: 10.1097/BOT.0b013e31825cf8fb.</citation>
    <PMID>22576645</PMID>
  </reference>
  <reference>
    <citation>Morgan SL, Weinsier RL. Fundamentals of clinical nutrition, Mosby, St. Louis 1998. p.3</citation>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Legacy Health System</investigator_affiliation>
    <investigator_full_name>Eric Anderson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

